DaVita has announced the acquisition of transplant software company MedSleuth, which works with US transplant centres to improve experiences and outcomes for kidney and liver transplant patients.
With this acquisition, DaVita is deepening its efforts to fuel transplant innovation, underscoring its commitment to improve care at every stage and setting along a patient’s kidney care journey—according to a company press release.
“Kidney transplantation is a life-changing option for most people with kidney failure—one that is limited today by supply and complexity,” said DaVita CEO Javier Rodriguez. “MedSleuth has built a powerful platform that can help increase patients’ access to transplantation. We are looking forward to supporting the team to accelerate innovation and help streamline the transplant process for transplant candidates, transplant centres, physicians and care teams.”
The release states that MedSleuth’s innovative software can help not only streamline the process of evaluating transplant candidates and keep them active on the waitlist, but may help increase the rate of transplantation through living donation as well. It can also make it easier for transplant candidates’ doctors and care teams to help support them along the transplant journey.
BREEZE, the company’s flagship product, helps remove certain barriers for potential kidney and liver donors and recipients by remotely gathering relevant clinical and demographic information, and sharing it with participating transplant centres.
MATCHGRID, MedSleuth’s paired exchange platform, uses optimisation algorithms to find chains for paired donation. This helps transplant centre clinicians rapidly match living organ donors with recipients who have willing, healthy but incompatible donors.
“We knew DaVita was the best long-term home for MedSleuth because we share a common vision to increase access to transplantation,” said James Kalamas, CEO and founder of MedSleuth. “Together, we will continue reimagining the transplant experience to help improve the lives of transplant patients.”
Kalamas will continue to lead the business, which will operate as a wholly-owned subsidiary of DaVita, the release notes.
